Influential cancer group rolls out first set of 'affordability' ratings on cancer drugs

The National Comprehensive Cancer Network unveiled its first set of "evidence blocks" that include cost information on oncology drugs; this first round focuses on chronic myelogenous leukemia (CML) and multiple myeloma. Drugs from Bristol-Myers Squibb ($BMY), Novartis ($NVS), Johnson & Johnson ($JNJ), and Celgene ($CELG), among others, were assessed on efficacy, safety and affordability. More from FiercePharmaMarketing